Gyre Therapeutics
GYRE
49 hedge funds and large institutions have $55.3M invested in Gyre Therapeutics in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 23 closing their positions.
66% more call options, than puts
Call options by funds: $196K | Put options by funds: $118K
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.78% less ownership
Funds ownership: 9.12% → 8.34% (-0.78%)
17% less capital invested
Capital invested by funds: $66.4M → $55.3M (-$11.1M)
22% less funds holding
Funds holding: 63 → 49 (-14)
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$5.93M |
| 2 |
Morgan Stanley
New York
|
+$1.96M |
| 3 |
2L
22NW LP
Seattle,
Washington
|
+$1.1M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$705K |
| 5 |
Goldman Sachs
New York
|
+$673K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.56M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.34M |
| 3 |
First Manhattan
New York
|
-$2.08M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.58M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.47M |
GYRE Hedge Fund Activity: Q2 2019 in Review
49 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2019, worth a combined $55.3M — down 17% from $66.4M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of GYRE and 11 opened new positions — a net loss of 12 holders — while 16 trimmed existing stakes and 19 added.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $5.93M. The largest seller was BlackRock, cutting an estimated $4.56M.
- 49 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2019, down from 63 in Q1 2019.
- Funds reported $55.3M of Gyre Therapeutics stock for Q2 2019, down 17% quarter-over-quarter.
- 11 funds opened new Gyre Therapeutics positions in Q2 2019 and 23 closed out, a net change of -12 holders.
- The largest Gyre Therapeutics buyer in Q2 2019 was Mangrove Partners, an estimated $5.93M added.
- The largest Gyre Therapeutics seller in Q2 2019 was BlackRock, an estimated $4.56M sold.
Based on aggregated 13F filings for Q2 2019.